CL2020002202A1 - Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza - Google Patents

Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza

Info

Publication number
CL2020002202A1
CL2020002202A1 CL2020002202A CL2020002202A CL2020002202A1 CL 2020002202 A1 CL2020002202 A1 CL 2020002202A1 CL 2020002202 A CL2020002202 A CL 2020002202A CL 2020002202 A CL2020002202 A CL 2020002202A CL 2020002202 A1 CL2020002202 A1 CL 2020002202A1
Authority
CL
Chile
Prior art keywords
pyrazino
pyrrolo
pyridazine
dione
tetrahydro
Prior art date
Application number
CL2020002202A
Other languages
English (en)
Inventor
Maxime Dauphinais
Rama Jain
Dennis Christofer Koester
James R Manning
Vanessa Marx
Daniel Poon
Lifeng Wan
Xiaojing Michael Wang
Aregahegn Yifru
Qian Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2020002202A1 publication Critical patent/CL2020002202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se refiere a derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H-pirrolo[1';2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados de Fórmula (A) como inhibidores de la replicación del ortomixovirus para tratar la influenza. (Fórmula A) (A) Un compuesto específico preferido es, por ejemplo, (9aR,10S)-10-((S)-(4-fluorofenil)(3- (trifluorometil)fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7H-pirrolo[1';2':4,5]pirazino[1,2-b]piridazin-3,5-diona (ejemplo 1).
CL2020002202A 2018-02-28 2020-08-26 Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza CL2020002202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862636378P 2018-02-28 2018-02-28

Publications (1)

Publication Number Publication Date
CL2020002202A1 true CL2020002202A1 (es) 2021-01-15

Family

ID=65911219

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002202A CL2020002202A1 (es) 2018-02-28 2020-08-26 Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza

Country Status (19)

Country Link
US (2) US11629149B2 (es)
EP (1) EP3759113A1 (es)
JP (3) JP7065989B2 (es)
KR (2) KR20230031990A (es)
CN (1) CN111801333A (es)
AU (1) AU2019227250B2 (es)
BR (1) BR112020017121A2 (es)
CA (1) CA3092544A1 (es)
CL (1) CL2020002202A1 (es)
CR (1) CR20200372A (es)
EA (1) EA202091696A1 (es)
IL (2) IL305957A (es)
MX (2) MX2020008959A (es)
NZ (1) NZ767072A (es)
PE (1) PE20210403A1 (es)
PH (1) PH12020500660A1 (es)
SG (1) SG11202007718SA (es)
UA (1) UA126253C2 (es)
WO (1) WO2019166950A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
CN111801333A (zh) * 2018-02-28 2020-10-20 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8501542D0 (en) 1985-01-22 1985-02-20 Erba Farmitalia 4 5 6 7-tetrahydro-imidazo(4 5-clpyridine derivatives
AUPM354694A0 (en) 1994-01-27 1994-02-17 Biota Scientific Management Pty Ltd Chemical compounds
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US20070161639A1 (en) 2004-03-09 2007-07-12 Philip Jones Hiv integrase inhibitors
FR2901795A1 (fr) 2006-05-30 2007-12-07 Fourtillan Snc Derives de pyrimidino[1',6'-1,2]pyrido[3,4-b]indoles et leur utilisation en therapeutique
EP2341053B1 (en) 2008-10-31 2016-01-13 Shionogi&Co., Ltd. Cephalosporin having catechol group
JP5697163B2 (ja) 2009-03-26 2015-04-08 塩野義製薬株式会社 置換された３−ヒドロキシ−４−ピリドン誘導体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
TWI520959B (zh) 2009-06-15 2016-02-11 鹽野義製藥股份有限公司 經取代的多環胺甲醯吡啶酮衍生物及其用途
EP2516441B1 (en) 2009-12-23 2015-01-21 Elan Pharmaceuticals Inc. Pteridinones as inhibitors of polo-like kinase
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN103228653B (zh) 2010-09-24 2016-03-16 盐野义制药株式会社 被取代的多环性氨基甲酰基吡啶酮衍生物的前药
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
US9200009B2 (en) 2011-10-12 2015-12-01 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase inhibitory activity
US9278996B2 (en) 2012-09-20 2016-03-08 Celltrion, Inc. Dolastatin-10 derivative, method of producing the same and anticancer drug composition containing the same
US9045486B2 (en) 2013-01-08 2015-06-02 Savira Pharmaceuticals Gmbh Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
CN105530946A (zh) 2013-09-11 2016-04-27 南加利福尼亚大学 具有高度表达的fas配体的干细胞组合物
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
CA2923075C (en) * 2013-09-12 2022-07-26 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
EP3166951A1 (en) 2014-07-07 2017-05-17 Savira Pharmaceuticals GmbH Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
CA2979216A1 (en) * 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
ES2881776T3 (es) 2016-03-08 2021-11-30 Novartis Ag Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus
WO2017156407A1 (en) 2016-03-10 2017-09-14 Alios Biopharma, Inc. Method of preparing aza-pyridone compounds
EP3858835A1 (en) 2016-07-01 2021-08-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
KR20190014086A (ko) 2016-08-10 2019-02-11 시오노기세야쿠 가부시키가이샤 치환된 다환성 피리돈 유도체 및 그의 프로드러그를 함유하는 의약 조성물
JOP20170169A1 (ar) * 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
JP2019059697A (ja) 2017-09-28 2019-04-18 塩野義製薬株式会社 置換された多環性ピリダジン誘導体およびそのプロドラッグ
KR102477187B1 (ko) 2018-01-17 2022-12-12 장시 카이시 파마슈티컬 테크놀로지 컴퍼니 리미티드 피리돈 유도체, 이의 입체 이성질체 및 항인플루엔자 바이러스 약물로서의 응용
CN110041327B (zh) 2018-01-17 2022-01-21 江西彩石医药科技有限公司 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
CN111801333A (zh) * 2018-02-28 2020-10-20 诺华股份有限公司 作为正粘病毒复制抑制剂用于治疗流感的10-(二(苯基)甲基)-4-羟基-8,9,9a,10-四氢-7H-吡咯并[1’,2’:4,5]吡嗪并[1,2-b]哒嗪-3,5-二酮衍生物及相关化合物

Also Published As

Publication number Publication date
BR112020017121A2 (pt) 2020-12-22
CN111801333A (zh) 2020-10-20
PE20210403A1 (es) 2021-03-02
JP2021514984A (ja) 2021-06-17
AU2019227250A1 (en) 2020-09-03
PH12020500660A1 (en) 2021-06-28
US20200407366A1 (en) 2020-12-31
JP7065989B2 (ja) 2022-05-12
IL276901A (en) 2020-10-29
UA126253C2 (uk) 2022-09-07
US11629149B2 (en) 2023-04-18
JP2024033009A (ja) 2024-03-12
SG11202007718SA (en) 2020-09-29
US20230322793A1 (en) 2023-10-12
CA3092544A1 (en) 2019-09-06
AU2019227250B2 (en) 2021-11-04
MX2020008959A (es) 2020-10-05
IL276901B1 (en) 2023-11-01
IL305957A (en) 2023-11-01
KR20230031990A (ko) 2023-03-07
WO2019166950A1 (en) 2019-09-06
KR102521320B1 (ko) 2023-04-13
IL276901B2 (en) 2024-03-01
CR20200372A (es) 2020-10-26
MX2023000084A (es) 2023-02-09
JP2022048391A (ja) 2022-03-25
EP3759113A1 (en) 2021-01-06
EA202091696A1 (ru) 2021-01-27
KR20200125654A (ko) 2020-11-04
NZ767072A (en) 2024-03-22

Similar Documents

Publication Publication Date Title
CL2020002202A1 (es) Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h-pirrolo [1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicación del ortomixovirus para el tratamiento de la influenza
UY37847A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
PE20141540A1 (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
CY1119499T1 (el) Ενωσεις 6,7-διυδροπυραζολο[1,5-α]πυραζιν-4(5η)-ονης και η χρηση τους ως αρνητικοι αλλοστερικοι τροποποιητες των υποδοχεων mglur2
EA201100447A1 (ru) Органические соединения
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
NI201000145A (es) DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET.
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
PE20151748A1 (es) Inhibidores de bace1
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
GT201700220A (es) Derivados de pirazol útiles como inhibidores de proteína activadora de 5-lipoxigenasa (flap)
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
PH12019500597A1 (en) CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
PH12020550761A1 (en) 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINONE DERIVATIVE AND MEDICAL USE THEREOF
CU24543B1 (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
PE20231097A1 (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso